Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Opana ER

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Oxymorphone is a semisynthetic extended release opiate used to treat moderate to severe chronic pain. The Food and Drug… Expand
  • figure 1
  • figure 2
Is this relevant?
Review
2017
Review
2017
Objectives Prescription drug abuse is a major public health problem in the United States, with the rate of opioid-related deaths… Expand
Is this relevant?
2017
2017
Legal formalities impose barriers to creating advance directives. Eliminating legal requirements would allow such documents to be… Expand
Is this relevant?
2017
2017
Opana ER (oxymorphone) is an opioid drug available throughout the United States, and intravenous abuse of the crushed oral… Expand
  • figure 1
  • figure 2
Is this relevant?
Review
2016
Review
2016
s The Journal of Pain S85 (adjusted HR 0.42, 95% CI 0.02-2.08). Outpatient use of fentanyl, codeine, or morphine was associated… Expand
Is this relevant?
2014
2014
Preventing prescription opioid overdose deaths is a public health priority. Deaths from these medications exceed deaths from all… Expand
Is this relevant?
2014
2014
We report the case of a 22 year-old-woman who presented with upper extremity cellulitis secondary to an infiltration of illicit… Expand
Is this relevant?
2014
2014
There have been recent reports and warnings of a thrombotic thrombocytopenic purpura-like illness associated with intravenous… Expand
  • table 1
  • figure 1
Is this relevant?
2013
2013
On August 13, 2012, a nephrologist reported to the Tennessee Department of Health (TDH) three cases of unexplained thrombotic… Expand
  • table 1
  • table 2
Is this relevant?
Review
2007
Review
2007
Opana® ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to… Expand
Is this relevant?